5th Annual RAS-Targeted Drug Development Summit

Multimodal Real-World Data for Accelerating Translational Research & De-Risking KRAS Drug Development

• The recent development of KRAS G12C inhibitors underscores the potential to target additional KRAS variants and develop combination therapeutic strategies
• Harmonized multimodal data sources can help KRAS researchers:
• Identify co-alterations and other biomarkers associated with response
• Select the most appropriate patient populations to enroll in clinical studies
• Validate clinical trial designs
• Data-driven approach to KRAS-targeted drug development will continue to help biopharma organizations bring these important treatments to patients faster and at a lower cost